Biotech in China Is Just Getting Started, Says Loncar Investments’s CEO

The video discusses the burgeoning biotech sector in China, likening it to the early days of the US biotech industry. Key factors driving this growth include regulatory reforms, entrepreneurial activity, and changes in the Hong Kong Stock Exchange. The speaker highlights promising companies like Zylab and Innovent Biologics, emphasizing their global ambitions and innovative drug developments. To navigate investment risks, a long-term outlook and diversification are recommended, with the China Biopharma index serving as a tool to track top companies in the sector.

What is the significance of the China Biopharma index?

What advice is given to investors regarding the biotech sector?